RhoB: Team Oncogene or Team Tumor Suppressor?

Overview

Journal Genes (Basel)

Publisher MDPI

Date 2018 Feb 2

PMID 29385717

Citations 28

Authors

Julia A Ju

Daniele M Gilkes

Affiliations

Soon will be listed here.

Abstract

Although Rho GTPases RhoA, RhoB, and RhoC share more than 85% amino acid sequence identity, they play very distinct roles in tumor progression. RhoA and RhoC have been suggested in many studies to contribute positively to tumor development, but the role of RhoB in cancer remains elusive. RhoB contains a unique C-terminal region that undergoes specific post-translational modifications affecting its localization and function. In contrast to RhoA and RhoC, RhoB not only localizes at the plasma membrane, but also on endosomes, multivesicular bodies and has even been identified in the nucleus. These unique features are what contribute to the diversity and potentially opposing functions of RhoB in the tumor microenvironment. Here, we discuss the dualistic role that RhoB plays as both an oncogene and tumor suppressor in the context of cancer development and progression.

Citing Articles

RhoB regulates prostate cancer cell proliferation and docetaxel sensitivity via the PI3K-AKT signaling pathway.

Sheng T, Su H, Yao L, Qu Z, Liu H, Shao W BMC Cancer. 2025; 25(1):354.

PMID: 40011853 PMC: 11863435. DOI: 10.1186/s12885-025-13762-4.

Downregulation of RhoB Inhibits Cervical Cancer Progression and Enhances Cisplatin Sensitivity.

Wang W, Jia Y, Liu Y, Lv X, Guo L, Meng S Genes (Basel). 2024; 15(9).

PMID: 39336777 PMC: 11431011. DOI: 10.3390/genes15091186.

MiR-21-5p knockdown inhibits epithelial to mesenchymal transition in A549 lung adenocarcinoma cells by upregulating RhoB.

Khair H, Karagoz I Mol Biol Rep. 2024; 51(1):837.

PMID: 39042337 DOI: 10.1007/s11033-024-09794-x.

RhoB expression associated with chemotherapy response and prognosis in colorectal cancer.

Kopsida M, Liu N, Kotti A, Wang J, Jensen L, Jothimani G Cancer Cell Int. 2024; 24(1):75.

PMID: 38355625 PMC: 10867990. DOI: 10.1186/s12935-024-03236-1.

Wavelet scattering networks in deep learning for discovering protein markers in a cohort of Swedish rectal cancer patients.

Pham T, Sun X Cancer Med. 2023; 12(23):21502-21518.

PMID: 38014709 PMC: 10726782. DOI: 10.1002/cam4.6672.

References

Sabatel C, Malvaux L, Bovy N, Deroanne C, Lambert V, Gonzalez M . MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells. PLoS One. 2011; 6(2):e16979. PMC: 3037403. DOI: 10.1371/journal.pone.0016979. View

Ho C, Kurman R, Dehari R, Wang T, Shih I . Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res. 2004; 64(19):6915-8. DOI: 10.1158/0008-5472.CAN-04-2067. View

Porter A, Papaioannou A, Malliri A . Deregulation of Rho GTPases in cancer. Small GTPases. 2016; 7(3):123-38. PMC: 5003542. DOI: 10.1080/21541248.2016.1173767. View

Yoneda M, Hirokawa Y, Ohashi A, Uchida K, Kami D, Watanabe M . RhoB enhances migration and MMP1 expression of prostate cancer DU145. Exp Mol Pathol. 2009; 88(1):90-5. DOI: 10.1016/j.yexmp.2009.09.010. View

Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B . Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer. 2002; 87(6):635-44. PMC: 2364248. DOI: 10.1038/sj.bjc.6600510. View

Adjei A, Erlichman C, Davis J, Cutler D, Sloan J, Marks R . A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. 2000; 60(7):1871-7. View

Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y . Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res. 2003; 9(7):2632-41. View

Liu Ax , Cerniglia G, Bernhard E, Prendergast G . RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage. Proc Natl Acad Sci U S A. 2001; 98(11):6192-7. PMC: 33444. DOI: 10.1073/pnas.111137198. View

Heasman S, Ridley A . Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol. 2008; 9(9):690-701. DOI: 10.1038/nrm2476. View

10.

van Golen K, Wu Z, Qiao X, Bao L, Merajver S . RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res. 2000; 60(20):5832-8. View

11.

Gilkes D . Implications of Hypoxia in Breast Cancer Metastasis to Bone. Int J Mol Sci. 2016; 17(10). PMC: 5085702. DOI: 10.3390/ijms17101669. View

12.

Skuli N, Monferran S, Delmas C, Lajoie-Mazenc I, Favre G, Toulas C . Activation of RhoB by hypoxia controls hypoxia-inducible factor-1alpha stabilization through glycogen synthase kinase-3 in U87 glioblastoma cells. Cancer Res. 2006; 66(1):482-9. DOI: 10.1158/0008-5472.CAN-05-2299. View

13.

Fritz G, Kaina B . Ras-related GTPase RhoB forces alkylation-induced apoptotic cell death. Biochem Biophys Res Commun. 2000; 268(3):784-9. DOI: 10.1006/bbrc.2000.2211. View

14.

Mazieres J, Tovar D, He B, Nieto-Acosta J, Marty-Detraves C, Clanet C . Epigenetic regulation of RhoB loss of expression in lung cancer. BMC Cancer. 2007; 7:220. PMC: 2222678. DOI: 10.1186/1471-2407-7-220. View

15.

Johnston S, Hickish T, Ellis P, Houston S, Kelland L, Dowsett M . Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol. 2003; 21(13):2492-9. DOI: 10.1200/JCO.2003.10.064. View

16.

Tan Y, Yin H, Zhang H, Fang J, Zheng W, Li D . Sp1-driven up-regulation of miR-19a decreases RHOB and promotes pancreatic cancer. Oncotarget. 2015; 6(19):17391-403. PMC: 4627316. DOI: 10.18632/oncotarget.3975. View

17.

Wojtkowiak J, Gibbs R, Mattingly R . Working together: Farnesyl transferase inhibitors and statins block protein prenylation. Mol Cell Pharmacol. 2010; 1(1):1-6. PMC: 2858423. DOI: 10.4255/mcpharmacol.09.01. View

18.

Prendergast G, Khosravi-Far R, Solski P, KURZAWA H, Lebowitz P, Der C . Critical role of Rho in cell transformation by oncogenic Ras. Oncogene. 1995; 10(12):2289-96. View

19.

Medale-Giamarchi C, Lajoie-Mazenc I, Malissein E, Meunier E, Couderc B, Berge Y . RhoB modifies estrogen responses in breast cancer cells by influencing expression of the estrogen receptor. Breast Cancer Res. 2013; 15(1):R6. PMC: 3672819. DOI: 10.1186/bcr3377. View

20.

Lebowitz P, Davide J, Prendergast G . Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol Cell Biol. 1995; 15(12):6613-22. PMC: 230914. DOI: 10.1128/MCB.15.12.6613. View